Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Aug 21, 2019 10:15am
204 Views
Post# 30050160

RE:RE:RE:Somebody rang the alarm bell

RE:RE:RE:Somebody rang the alarm bellRiverrow ...Ph. 2 trials cannot be concentrated at only 1 location.  It would raise too many doubts about repeatability of the process, if concentrated within the same UHN team. 

One of the purposes of these Ph. 2b trials is to demonstrate that a new technology can be applied/executed correctly by a growing number of specialists (urologists in our case) spanned across a wider geography, over and over, with the same rate of success when it comes to execution.  Just like the pool of patients will also have to represent an accurate image of the variety of ethnicity of patients that can qualify for such technology.

To ensure urologists of other regions for this Ph. 2b execute properly, PMH will send its staff to these other locations to ensure proper training.  Mass training will occur in Toronto when commercial approval will have been granted.

That's the way this industry (and many others) work.  And it makes sense.

_________________

riverrrow - (8/21/2019 8:53:00 AM) 
RE:RE:Somebody rang the alarm bell
Personally I would prefer to see TLT treat all their Canadian patients at one site by one team to ensure consistency even if TLT has to pay all the patients expenses. GLTA.
Bullboard Posts